A Phase II study of high-dose tamoxifen in patients with hormone- refractory prostate cancer

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2366-2373

  Bergan, Raymond C ^a,c   Reed, Eddie ^a   Myers, Charles E ^b   Headlee, Donna ^a   Brawley, Otis ^a   Cho, Hea Kyoung ^a   Figg, W Douglas ^a   Tompkins, Anne ^a   Linehan, W Marston ^a   Kohler, David ^a   Steinberg, Seth M ^a   Blagosklonny, Mikhail V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE C; TAMOXIFEN; TAMOXIFEN CITRATE; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 0032862225     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1999.
2. Robson, M., and Dawson, N. How is androgen-dependent metastatic prostate cancer best treated? Hematol. Oncol. Clin. North Am., 10: 727-747, 1996.
3. Raghavan, D., Koczwara, B., and Javle, M. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur. J. Cancer, 33: 566-574, 1997.
4. Scher, H. I., Mazumdar, M., and Kelly, W. K. Clinical trials in relapsed prostate cancer: defining the target. J. Natl. Cancer Inst., 88: 1623-1634, 1996.
5. Slovin, S. F., Livingston, P. O., Rosen, N., Sepp-Lorenzino, L., Kelly, W. K., Mendelsohn, J., and Scher, H. I. Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Semin. Oncol., 23: 41-48, 1996.
6. Pienta, K. J., and Lehr, J. E. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J. Urol., 149: 1622-1625, 1993.
7. Denmeade, S. R., Isaacs, J. T., Joseph, I. B., Vukanovic, J., and Isaacs, J. T. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer: antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Adv. Pharmacol., 35: 281-306, 1996.
8. Bergan, R., Kyle, E., Nguyen, P., Trepel, J., and Neckers, L. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to β-1-integrin. Clin. Exp. Metastasis, 14: 389-398, 1996.
9. Rohlff, C., Blagosklonny, M. V., Kyle, E., Kesari, A., Kirn, I. Y., Zelner, D. J., Hakim, F., Trepel, J., and Bergan, R. C. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1. Prostate, 37: 51-59, 1998.
10. Kyle, E., Neckers, L., Takimoto, C., Curt, G., and Bergan, R. C. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol. Pharmacol., 51: 193-200, 1997.
11. Pienta, K. J., Redman, B., Hussain, M., Cummings, G., Esper, P. S., Appel, C., and Flaherty, L. E. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncol., 13: 797, 1995.
12. Bergan, R. C., Blagosklonny, M., Dawson, N., Headlee, D., Figg, W. D., Neckers, L., and Myers, C. E. Significant activity by high dose tamoxifen in hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol., 14: 32, 1995.
13. O'Brian, C. A., Liskamp, R. M., Solomon, D. H., and Weinstein, I. B. Inhibition of protein kinase C by tamoxifen. Cancer Res., 45: 2462-2465, 1985.
14. O'Brian, C. A., Liskamp, R. M., Solomon, D. H., and Weinstein, I. B. Triphenylethylenes: a new class of protein kinase C inhibitors. J. Natl. Cancer Inst., 76: 1243-1246, 1986.
15. Sehgal, I., Baley, P. A., and Thompson, T. C. Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res, 56: 3359-3365, 1996.
16. Kim, I. Y., Ahn, H. J., Zelner, D. J., Shaw, J. W., Sensibar, J. A., Kim, J. H., Kato, M., and Lee, C. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res., 56: 44-48, 1996.
17. Kim, I. Y., Ahn, H. J., Zelner, D. J., Shaw, J. W., Lang, S., Kato, M., Oefelein, M. G., Miyazono, K., Nemeth, J. A., Kozlowski, J. M., and Lee, C. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin. Cancer Res., 2: 1255-1261, 1996.
18. Muir, G. H., Butta, A., Shearer, R. J., Fisher, C., Dearnaley, D. P., Flanders, K. C., Sporn, M. B., and Colletta, A. A. Induction of transforming growth factor β in hormonally treated human prostate cancer. Br. J. Cancer, 69: 130-134, 1994.
19. Wilding, G., Zugmeier, G., Knabbe, C., Flanders, K., and Gelmann, E. Differential effects of transforming growth factor β on human prostate cancer cells in vitro. Mol. Cell. Endocrinol., 62: 79-87, 1989.
20. Miniati, D. N., Chang, Y., Shu, W. P., Peehl, D. M., and Liu, B. C. Role of prostatic basal cells in the regulation and suppression of human prostate cancer cells. Cancer Lett., 104: 137-144, 1996.
21. Roberson, K. M., Penland, S. N., Padilla, G. M., Selvan, R. S., Kim, C. S., Fine, R. L., and Robertson, C. N. Fenretinide: induction of apoptosis and endogenous transforming growth factor β in PC-3 prostate cancer cells. Cell Growth Differ., 8: 101-111, 1997.
22. Hsing, A. Y., Kadomatsu, K., Bonham, M. J., and Danielpour, D. Regulation of apoptosis induced by transforming growth factor-β1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res., 56: 5146-5149, 1996.
23. Trump, D. L., Smith, D. C., Ellis, P. G., Rogers, M. P., Schold, S. C., Winer, E. P., Panella, T. J., Jordan, V. C., and Fine, R. L. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J. Natl. Cancer Inst., 84: 1811-1816, 1992.
24. Couldwell, W. T., Weiss, M. H., DeGiorgio, C. M., Weiner, L. P., Hinton, D. R., Ehresmann, G. R., Conti, P. S., and Apuzzo, M. L. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery, 32: 485-490, 1993.
25. Ducharme, J., Fried, K., Shenouda, G., Leyland-Jones, B., and Wainer, I. W. Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. Br. J. Clin. Pharmacol., 43: 189-193, 1997.
26. Ganz, P. A., Haskell, C. M., Figlin, R. A., La Soto, N., and Siau, J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index-Cancer. Cancer (Phila.), 61: 849-856, 1988.
27. Schipper, H., Clinch, J., McMurray, A., and Levitt, M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer development and validation. J Clin Oncol, 2: 472-483, 1984.
28. Atkinson, E. N., and Brown, B. W. Confidence limits for probability of response in multistage Phase II clinical trials. Biometrics, 41: 741-744, 1985.
29. Kaplan, E., and Meier, P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-458, 1958.
30. Franzen, P., Ichijo, H., and Miyazono, K. Different signals mediate transforming growth factor-β1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells. Exp. Cell Res., 207: 1-7, 1993.
31. Cloughesy, T. F., Woods, R. P., Black, K. L., Couldwell, W. T., Law, R. E., and Hinton, D. R. Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen. J. Neurooncol., 35: 39-45, 1997.
32. Mastronardi, L., Farah, J. O., Puzzilli, F., Qasho, R., and Lunardi, P. Clinical and radiographic stabilization of intracranial glioblastoma. Report of a case treated after surgery with tamoxifen. J. Neurosurg. Sci., 40: 129-133, 1996.
33. Couldwell, W. T., Hinton, D. R., He, S., Chen, T. C., Sebat, I., Weiss, M. H., and Law, R. E. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett., 345: 43-46, 1994.
34. Vertosick, F. T., Jr, Selker, R. G., Randall, M. S., Kristofik, M. P., and Rehn, T. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and N-desmethyltamoxifen in vitro. J. Neurooncol., 19: 97-103, 1994.
35. Pollack, I. F., and Kawecki, S. The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors. Pediatr. Neurosurg., 22: 281-288, 1995.
36. Spremulli, E., DeSimone, P., and Durant, J. A Phase II study Nolvadex: tamoxifen citrate in the treatment of advanced prostatic adenocarcinoma. Am. J. Clin. Oncol., 5: 149-153, 1982.
37. Click, J. H., Wein, A., Padavic, K., Negendank, W., Harris, D., and Brodovsky, H. Phase II trial of tamoxifen in metastatic carcinoma of the prostate. Cancer (Phila.), 49: 1367-1372, 1982.
38. Furr, B. J. A., and Jordan, V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25: 127-205, 1984.
39. Goethuys, H., Baert, L., Van Poppel, H., Lieskovsky, G., Brady, L. W., and Petrovich, Z. Treatment of metastatic carcinoma of the prostate. Am. J. Clin. Oncol., 20: 40-45, 1997.
40. Tormey, D. C., Lippman, M. E., Edwards, B. K., and Cassidy, J. G. Evaluation of tamoxifen doses with and without fluoxymester-one in advanced breast cancer. Ann. Intern. Med., 98: 139-144, 1983.
41. Papac, R. J., and Keohane, M. F. Hormonal therapy for metastatic renal cell carcinoma combined androgen and provera followed by high dose tamoxifen. Eur. J. Cancer, 29A: 997-999, 1993.
42. Nayfield, S. G., and Gorin, M. B. Tamoxifen-associated eye disease. A review. J. Clin. Oncol., 14: 1018-1026, 1996.